Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea
- PMID: 17963334
- PMCID: PMC2628143
- DOI: 10.3349/ymj.2007.48.5.779
Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea
Abstract
Purpose: The incidence of Candida bloodstream infections (BSI) has increased over the past two decades. The rank order of occurrence and the susceptibility to antifungals of the various Candida species causing BSI are important factors driving the establishment of empirical treatment protocols; however, very limited multi-institutional data are available on Candida bloodstream isolates in Korea.
Materials and methods: We investigated the susceptibility to azole antifungals and species distribution of 143 Candida bloodstream isolates recovered from eight university hospitals over a six-month period. Minimal inhibitory concentrations (MICs) of fluconazole, itraconazole, and voriconazole for each isolate were determined by the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI).
Results: The Candida species recovered most frequently from the blood cultures was C. albicans (49%), followed by C. parapsilosis (22%), C. tropicalis (14%), and C. glabrata (11%). The MIC ranges for the Candida isolates were 0.125 to 64 microg/mL for fluconazole, 0.03 to 2 microg/mL for itraconazole, and 0.03 to 1 microg/mL for voriconazole. Overall, resistance to fluconazole was found in only 2% of the Candida isolates (3/143), while the dose-dependent susceptibility was found in 6% (8/143). The resistance and dose-dependent susceptibility of itraconazole were found in 4% (6/143) and 14% (20/143) of the isolates, respectively. All bloodstream isolates were susceptible to voriconazole (MIC, < or = 1 microg/mL).
Conclusion: Our findings show that C. albicans is the most common cause of Candida-related BSI, followed by C. parapsilosis, and that the rates of resistance to azole antifungals are still low among bloodstream isolates in Korea.
Similar articles
-
[Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].Mikrobiyol Bul. 2016 Jan;50(1):122-32. doi: 10.5578/mb.10682. Mikrobiyol Bul. 2016. PMID: 27058336 Turkish.
-
Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.Med Mycol. 2009 Mar;47(2):137-43. doi: 10.1080/13693780802144339. Epub 2008 Jun 27. Med Mycol. 2009. PMID: 18651308
-
In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.Ann Lab Med. 2013 May;33(3):167-73. doi: 10.3343/alm.2013.33.3.167. Epub 2013 Apr 17. Ann Lab Med. 2013. PMID: 23667842 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.Clin Microbiol Rev. 2006 Apr;19(2):435-47. doi: 10.1128/CMR.19.2.435-447.2006. Clin Microbiol Rev. 2006. PMID: 16614256 Free PMC article. Review.
Cited by
-
Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.Mycopathologia. 2011 Sep;172(3):187-99. doi: 10.1007/s11046-011-9413-y. Epub 2011 Mar 20. Mycopathologia. 2011. PMID: 21424603
-
Comparison of nosocomial candidemia of pediatric and adult cases in 2-years period at a Turkish university hospital.Eurasian J Med. 2011 Aug;43(2):87-91. doi: 10.5152/eajm.2011.20. Eurasian J Med. 2011. PMID: 25610170 Free PMC article.
-
Time to positivity of blood cultures causing candidemia and its relation to mortality.Iran J Microbiol. 2024 Apr;16(2):263-272. doi: 10.18502/ijm.v16i2.15361. Iran J Microbiol. 2024. PMID: 38854986 Free PMC article.
-
Candida parapsilosis, an emerging fungal pathogen.Clin Microbiol Rev. 2008 Oct;21(4):606-25. doi: 10.1128/CMR.00013-08. Clin Microbiol Rev. 2008. PMID: 18854483 Free PMC article. Review.
-
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.Korean J Intern Med. 2011 Jun;26(2):220-52. doi: 10.3904/kjim.2011.26.2.220. Epub 2011 Jun 1. Korean J Intern Med. 2011. PMID: 21716917 Free PMC article. Review.
References
-
- Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239–244. - PubMed
-
- Shin JH, Kim MN, Shin DH, Jung SI, Kim KJ, Cho D, et al. Genetic relatedness among Candida tropicalis isolates from sporadic cases of fungemia in two university hospitals in Korea. Infect Control Hosp Epidemiol. 2004;25:634–640. - PubMed
-
- Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis. 1999;34:213–220. - PubMed
-
- Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999;29:1164–1170. - PubMed
-
- Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39:3254–3259. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous